Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E in Patients With Type 2 Diabetes Mellitus
Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E in Patients With Type 2 Diabetes Mellitus
Conjugated linoleic acids (CLAs) comprise a family of linoleic acid (18:2n-6; LA) isomers
 that are formed by biohydrogenation and oxidation processes in nature. The main form of CLA,
 cis-9, trans-11-18:2, can be produced directly by bacterial hydrogenation in the rumen or by
 delta-9 desaturation of the co-product vaccenic acid (trans-11-18:1) in most mammalian
 tissues including man. The second most abundant isomer of CLA is the trans-10, cis-12-18:2
 form. Observations clearly emphasize that differences exist between mammalian species in
 their response to CLAs with mice being the most sensitive. The majority of studies on body
 compositional effects (i.e. fat loss, lean gain), on cancer and cardiovascular disease
 attenuation, on insulin sensitivity and diabetes and on immune function have been conducted
 with a variety of animal models. Recent studies indicate that some but not all of the effects
 observed in animals also pertain to human volunteers. Reports of detrimental effects of CLA
 intake appear to be largely in mice and due mainly to the trans-10, cis-12 isomer.
 Suggestions of possible deleterious effects in man due to an increase in oxidative lipid
 products (isoprostanes) with trans-10, cis-12 CLA ingestion require substantiation.
 Unresponsiveness to antioxidants of these non-enzymatic oxidation products casts some doubt
 on their physiological relevance. We hypothesized that supplementation with CLA + an
 antioxidant (vitamin E) in patients with diabetes mellitus may have beneficial effects on
 glycemic control and insulin sensitivity.
Inclusion Criteria:

 -  Diagnosis of type 2 diabetes mellitus > 5 years

 -  HbA1c ≤ 9%

 -  Overweight or obese (BMI ≥ 25 kg/m2 and ≤ 30 kg/m2)

 -  Age ≥ 30 and ≤ 70 years (postmenopausal if female)

 -  Stable medical therapy for past 3 months

 -  Stable serum glucose for past 3 months (128-180 mg/Dl)

 -  Age between 30 to 50

 -  Use of metformin

 -  TG < 240 mg/Dl

 -  No alcohol, no insulin, no smoke

 -  No pregnancy, no menopause

 Exclusion Criteria:

 -  Personal history of coronary heart disease

 -  Cerebrovascular disease or vascular disease

 -  Renal or hepatic disease

 -  Inflammatory diseases and thyroid diseases within the last years

 -  Use of drugs known to affect glycemic control, beta blockers, any change in daily
 activity profile, and diet